While the Overweight rating suggests that Morgan Stanley still sees growth potential in ShockWave Medical, the reduction in the price target may reflect a reassessment of the company's near-term prospects, possibly due to market conditions or performance metrics. This could lead to a neutral short-term impact on the stock as investors digest the mixed signals of continued confidence in the company's performance against a lower expected valuation.